European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry
NCT ID: NCT00378391
Last Updated: 2007-06-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1800 participants
OBSERVATIONAL
2005-11-30
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This registry is designed to collect data on approximately 1800 patients during a 12 month enrollment period in up to 20 interventional cardiology centres with hospital transfer networks from all over Europe.
Analysis of this registry should allow to monitor transfer timelines of patients arriving to the cath-lab from the regional hospital with or without upstream start of abciximab and scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across Europe in regard to the impact that time of various stages of the treatment chain may have on clinical outcomes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
DEFINED_POPULATION
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All consecutive STEMI patients \>=18years arriving to the Cath Lab hospital (invasive facility center) from transfer.
* Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital:
1. transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or
2. after being picked-up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board.
CENTRES:
* Provide 24 hour/7 days on duty PCI service.
* Has an established regional hospital referral network with \>=8 patients/month arriving from transfer (as defined above).
* A rate of \>=10% of these transfer patients who receive upstream abciximab before or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU of the Cath Lab hospital will not be considered as upstream start of abciximab.
Exclusion Criteria
* Patients from controlled clinical trials shall be included as long as their actual treatment is fully known. Thus, participants from randomized trials with blinded treatment cannot be included in this registry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Foundation for Medical Research in Krakow, Poland
UNKNOWN
Jagiellonian University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dariusz Dudek, Assoc. Prof.
Role: PRINCIPAL_INVESTIGATOR
Cardiac Catheterization Laboratories, Jagiellonian University Medical College
Zbigniew Siudak, MD
Role: STUDY_CHAIR
Cardiac Catheterization Laboratories, Jagiellonian University Medical College
Lukasz Partyka, MD, PhD
Role: STUDY_DIRECTOR
KCRI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Central Hospital
Helsinki, , Finland
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Villingen, , Germany
San Donato Hospital
Arezzo, , Italy
Ospedale Carlo Poma
Mantova, , Italy
Ospedale G.Pasquinucci
Massa, , Italy
Santa Maria Nuova Hospital Reggio Emilia
Reggio Emilia, , Italy
Ospedale S.Maria di Ca Foncello
Treviso, , Italy
Cardiac Catheterization Laboratories Jagiellonian University Medical College, University Hospital
Krakow, , Poland
Department of Interventional Cardiology, John Paul II Hospital
Krakow, , Poland
Szpital Wojewodzki w Przemyslu
Przemyśl, , Poland
Szpital im. Szczeklika Tarnow
Tarnów, , Poland
University Medical Center Ljubljana
Ljubljana, , Slovenia
Hospital Juan Canalejo
A Coruña, , Spain
Hospital Clinico Universitario
Santiago de Compostela, , Spain
Linköping University Hospital
Linköping, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dziewierz A, Siudak Z, Rakowski T, Kleczynski P, Zasada W, Dubiel JS, Dudek D. Impact of direct stenting on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry). Catheter Cardiovasc Interv. 2014 Nov 15;84(6):925-31. doi: 10.1002/ccd.25266. Epub 2014 Jul 29.
Dziewierz A, Siudak Z, Rakowski T, Kleczynski P, Dubiel JS, Dudek D. Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry). J Thromb Thrombolysis. 2013 Oct;36(3):240-6. doi: 10.1007/s11239-012-0826-3.
Dziewierz A, Mielecki W, Siudak Z, Rakowski T, Janzon M, Birkemeyer R, Zasada W, Dubiel JS, Dudek D. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry). Atherosclerosis. 2012 Jul;223(1):212-8. doi: 10.1016/j.atherosclerosis.2012.04.018. Epub 2012 May 15.
Siudak Z, Zawislak B, Dziewierz A, Rakowski T, Jakala J, Bartus S, Noworolnik B, Zasada W, Dubiel JS, Dudek D. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry. Coron Artery Dis. 2010 Aug;21(5):292-7. doi: 10.1097/MCA.0b013e32833aa6d1.
Dudek D, Siudak Z, Janzon M, Birkemeyer R, Aldama-Lopez G, Lettieri C, Janus B, Wisniewski A, Berti S, Olivari Z, Rakowski T, Partyka L, Goedicke J, Zmudka K; EUROTRANSFER Registry Investigators. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry. Am Heart J. 2008 Dec;156(6):1147-54. doi: 10.1016/j.ahj.2008.08.004. Epub 2008 Oct 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H4S-PL-O067
Identifier Type: -
Identifier Source: org_study_id